We used the PLK1 inhibitor (BI2536) to treat cancer cell lines and compared expression levels of MHC class I (HLA-A, HLA-B, HLA-C, B2M, and TAP1 genes and their protein products) between the pre- and post- treated cell lines. This evidence concerns the gene B2M and cancer.